BioSpace

Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week showing its clinically meaningful benefit in older patients who are able to walk.

By BioSpace

1 min read
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights